{"nctId":"NCT01697501","briefTitle":"A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253","startDateStruct":{"date":"2012-11-08","type":"ACTUAL"},"conditions":["Hepatitis B, Chronic"],"count":88,"armGroups":[{"label":"Chronic hepatitis B patients","type":"EXPERIMENTAL","interventionNames":["Other: Interleukin 28B testing"]}],"interventions":[{"name":"Interleukin 28B testing","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients, \\>/= 18 years of age\n* Chronic hepatitis B\n* Previous participation in study ML18253\n* Administration of at least one dose of the study drug during ML18253 study\n\nExclusion Criteria:\n\n* Patients not satisfying the above inclusion criteria will not be enrolled in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Viral Response (SVR) Defined as HBV DNA ≤ 2000 IU/ml at IL28B Genotype rs12979860 at End of Follow-up (EoF)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"17.1","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"17.6","spread":null},{"groupId":"OG004","value":"18.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With SVR Defined as HBV DNA ≤ 2000 IU/ml at IL28B Genotype rs8099917 at EoF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"12.9","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"11.8","spread":null},{"groupId":"OG004","value":"18.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBV DNA ≤ 2000 IU/ml at IL28B Genotype rs12979860 at End of Treatment (EoT)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":null},{"groupId":"OG001","value":"65.9","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"62.7","spread":null},{"groupId":"OG004","value":"67.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBV DNA ≤ 2000 IU/ml at IL28B Genotype rs8099917 at EoT","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"54.8","spread":null},{"groupId":"OG002","value":"66.7","spread":null},{"groupId":"OG003","value":"55.9","spread":null},{"groupId":"OG004","value":"67.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBsAg < 0.05 IU/ml at IL28B Genotype rs12979860 at EoT and EoF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"2.0","spread":null},{"groupId":"OG004","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"3.9","spread":null},{"groupId":"OG004","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBsAg < 0.05 IU/ml at IL28B Genotype rs8099917 at EoT and EoF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBsAg ≤ 10 IU/ml at IL28B Genotype rs12979860 at EoT and EoF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"7.3","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"5.9","spread":null},{"groupId":"OG004","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"3.9","spread":null},{"groupId":"OG004","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HBsAg ≤ 10 IU/ml at IL28B Genotype rs8099917 at EoT and EoF","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"3.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":88},"commonTop":[]}}}